QuantaRx's follicle stimulating hormone immunoassay:
This article was originally published in Clinica
Executive Summary
The lateral flow immunoassay, called the QuantRx Biomedical Female Fertility test, is intended to aid women who are attempting to conceive. It can indirectly determine ovarian reserve - a measure of the capacity of the ovary to provides eggs that are capable of fertilisation - by measuring FSH in first morning urine. The over-the-counter test can produce results within 15 minutes, and can detect levels of FSH as low as 10ng/ml. The company is also developing a male fertility test, which is expected to reach the market in 2008.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.